Brief: Alzinova Says Preclinical Data Confirms Specificity, Efficacy Of ALZ-201
15/12/2021 07:09
Dec 15 (Reuters) - Alzinova AB ALZ.ST :
* PRECLINICAL DATA CONFIRM THE UNIQUE SPECIFICITY AND
DISEASE-MODIFYING POTENTIAL OF ALZINOVA'S MONOCLONAL ANTIBODY,
ALZ-201
* RESEARCH PROJECT EVALUATING ALZINOVA'S MONOCLONAL
ANTIBODY,
ALZ-201, HAS BEEN SUCCESSFULLY COMPLETED IN COLLABORATION WITH
AMSTERDAM UNIVERSITY MEDICAL CENTERS
* DATA FROM PROJECT CONFIRM UNIQUE SPECIFICITY AND
PRECLINICAL
EFFICACY OF ALZ-201 AND RELATED CLINICAL-STAGE VACCINE ALZ-101
Source text for Eikon: ID:nWkr8Zbs86
Further company coverage: ALZ.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))